Benjamin F. Edwards & Company Inc. raised its position in Becton, Dickinson and Company (NYSE:BDX) by 25.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,052 shares of the medical instruments supplier’s stock after acquiring an additional 1,224 shares during the period. Benjamin F. Edwards & Company Inc.’s holdings in Becton, Dickinson and were worth $1,186,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently made changes to their positions in BDX. Stock Yards Bank & Trust Co. raised its holdings in shares of Becton, Dickinson and by 30.8% in the third quarter. Stock Yards Bank & Trust Co. now owns 3,225 shares of the medical instruments supplier’s stock worth $632,000 after buying an additional 760 shares during the last quarter. Xact Kapitalforvaltning AB raised its holdings in shares of Becton, Dickinson and by 4.3% in the third quarter. Xact Kapitalforvaltning AB now owns 29,751 shares of the medical instruments supplier’s stock worth $5,830,000 after buying an additional 1,217 shares during the last quarter. Pineno Levin & Ford Asset Management Inc. raised its holdings in shares of Becton, Dickinson and by 1.9% in the third quarter. Pineno Levin & Ford Asset Management Inc. now owns 27,574 shares of the medical instruments supplier’s stock worth $5,403,000 after buying an additional 514 shares during the last quarter. Strs Ohio raised its holdings in shares of Becton, Dickinson and by 89.3% in the third quarter. Strs Ohio now owns 244,219 shares of the medical instruments supplier’s stock worth $47,854,000 after buying an additional 115,234 shares during the last quarter. Finally, Farmers & Merchants Investments Inc. raised its holdings in shares of Becton, Dickinson and by 2.1% during the third quarter. Farmers & Merchants Investments Inc. now owns 21,901 shares of the medical instruments supplier’s stock worth $4,292,000 after purchasing an additional 454 shares during the last quarter. Institutional investors own 86.70% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was first reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://www.watchlistnews.com/becton-dickinson-and-company-bdx-holdings-raised-by-benjamin-f-edwards-company-inc/1675310.html.

Several brokerages recently issued reports on BDX. BidaskClub raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a report on Monday, August 14th. Royal Bank Of Canada reissued a “hold” rating and set a $210.00 target price on shares of Becton, Dickinson and in a report on Wednesday, October 25th. Zacks Investment Research raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 target price for the company in a report on Tuesday. Cowen and Company reissued an “outperform” rating and set a $230.00 target price (up previously from $200.00) on shares of Becton, Dickinson and in a report on Monday, July 10th. Finally, Barclays PLC reissued an “equal weight” rating and set a $210.00 target price (up previously from $205.00) on shares of Becton, Dickinson and in a report on Thursday, August 10th. Four analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $205.79.

Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Wednesday, November 1st. The medical instruments supplier reported $2.40 EPS for the quarter, beating the Zacks’ consensus estimate of $2.37 by $0.03. The firm had revenue of $3.17 billion for the quarter, compared to analysts’ expectations of $3.14 billion. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The firm’s revenue was down 2.0% on a year-over-year basis. During the same period in the prior year, the company earned $2.12 EPS.

In related news, insider Gary M. Cohen sold 15,512 shares of the stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $203.77, for a total value of $3,160,880.24. Following the sale, the insider now directly owns 95,781 shares of the company’s stock, valued at approximately $19,517,294.37. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Linda M. Tharby sold 4,695 shares of the stock in a transaction dated Tuesday, August 22nd. The shares were sold at an average price of $200.48, for a total transaction of $941,253.60. Following the completion of the sale, the executive vice president now directly owns 18,670 shares in the company, valued at $3,742,961.60. The disclosure for this sale can be found here. Over the last three months, insiders sold 75,904 shares of company stock worth $15,242,688. 1.40% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.